PT Kalbe Farma Tbk 2014 AR2
The report highlights PT Kalbe Farma Tbk's performance in 2014, showcasing a 7.6% growth in net income to Rp2,065 billion and an 8.5% increase in net sales to Rp17,369 billion. Key achievements during the year include the commercial operation of a new oncology factory in Pulogadung, pioneering local production of cancer drugs, and the launch of ReGeniC, the first stem cell therapy unit in Indonesia. In sustainability, the company engaged over 4,200 employees in corporate social responsibility activities, reaching more than 25,000 beneficiaries through health, education, and environmental programs. Additionally, Kalbe reduced electricity consumption by an average of 400,000 kWh per month through power factor improvements.
Company: PT Kalbe Farma Tbk
Sector: Health Care
Country: Indonesia
Year: 2014
Type: AR2
Pages: 400
Back to company
PT Kalbe Farma Tbk
Annual Report
The report highlights PT Kalbe Farma Tbk's performance in 2014, showcasing a 7.6% growth in net income to Rp2,065 billion and an 8.5% increase in net sales to Rp17,369 billion. Key achievements during the year include the commercial operation of a new oncology factory in Pulogadung, pioneering local production of cancer drugs, and the launch of ReGeniC, the first stem cell therapy unit in Indonesia. In sustainability, the company engaged over 4,200 employees in corporate social responsibility activities, reaching more than 25,000 beneficiaries through health, education, and environmental programs. Additionally, Kalbe reduced electricity consumption by an average of 400,000 kWh per month through power factor improvements.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English, Indonesian
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees